CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses

Bhushan Dharmadhikari, Meihui Wu, Nur Sharalyn Abdullah, Sakti Rajendran, Nur Diana Ishak, Emily Nickles, Zulkarnain Harfuddin, and Herbert Schwarz

aDepartment of Physiology, and Immunology Programme, National University of Singapore, Singapore; bNUS Graduate School for Integrative Sciences and Engineering, National University of Singapore, Singapore

ABSTRACT
CD137 is expressed on activated T cells and NK cells, among others, and is a potent co-stimulator of antitumor immune responses. CD137 ligand (CD137L) is expressed by antigen presenting cells (APC), and CD137L reverse signaling into APC enhances their activity. CD137–CD137L interactions as main driver of type 1, cell-mediated immune responses explains the puzzling observation that CD137 agonists which enhance antitumor immune responses also ameliorate autoimmune diseases. Upon co-stimulation by CD137, Th1 CD4+ T cells together with Tc1 CD8+ T cells and NK cells inhibit other T cell subsets, thereby promoting antitumor responses and mitigating non-type 1 auto-immune diseases.

CD137 agonists enhance type 1, cell-mediated immune responses

CD137 (4-1BB, TNFRSF9) is increasingly recognized as a powerful inducer of antitumor immune responses. The potency of CD137 co-stimulation in enabling the immune system to eliminate tumors has been documented in a wide plethora of murine tumor models including mastocytoma, sarcoma, colon carcinoma, melanoma and lymphoma. In most studies, agonistic anti-CD137 antibodies were used to initiate CD137 signaling. In addition, a soluble recombinant CD137L protein and a CD137-specific aptamer have also been successfully tested as CD137 agonists in murine tumor models. Similarly, transgenic CD137L expression on lymphoma and Ewing’s tumor cells induced the expansion of tumor-specific cytotoxic T cells and limited tumor growth and metastatic spread. CD137 agonists also work synergistically with cancer vaccines and immune check point inhibitors in boosting antitumor immune responses.

CD137 was first cloned from T cells, on which its expression is activation-dependent. CD137 is expressed at higher levels on CD8+ T cells than on CD4+ T cells, and it mainly co-stimulates CD8+ T cells. Crosslinking of CD137 strongly enhances proliferation, IFNγ secretion and the cytolytic activity of T cells. T cell co-stimulation through CD137 occurs during cognate interaction of T cells with APC. Since only T cells that have been activated through the T cell receptor express CD137, T cell co-stimulation through CD137 is antigen-specific. This restricted expression of CD137 on antigen-specific T cells endows CD137 agonists with a high degree of specificity. Thus, the selective expression of CD137 on antigen-specific T cells may possibly allow a prescreening of patients who are likely to respond to a CD137 agonist-based immunotherapy.

The encouraging results in preclinical tumor models soon led to the humanization of existing murine anti-CD137 antibodies, as well as the screening of fully human antibodies, to be used in human cancer patients. However, the first clinical trials with agonistic anti-CD137 antibodies were discontinued in phase II after resulting in severe liver toxicities and deaths in several cancer patients. A more in-depth understanding of the CD137 biology, especially of the role of CD137 in natural killer (NK) cells has led to a revival of the use of anti-CD137 antibodies in cancer immunotherapy. CD137 can be expressed by NK cells and, similar as in T cells, the expression is activation-dependent. CD137 expression on NK cells is induced by Fc receptor signaling, and when stimulated by agonistic anti-CD137 antibodies, NK cells exert enhanced antitumor activity. Although CD137 expression on NK cells is not antigen-specific per se, the Fc receptor-mediated induction of CD137 expression only occurs at cells and tissues which have been opsonized by a therapeutic antibody, and therefore the specificity of the antibody determines in which tissues CD137 expression on NK cells is induced.

In the new approach, anti-CD137 antibodies are administered subsequent to the administration of antibodies that target antigens on the tumor cell surface (e.g. Her2/neu, epidermal growth factor receptor or CD20). The tumor antigen-targeting antibodies induce CD137 expression in adjacent NK cells.
which upon further co-stimulation by anti-CD137 antibodies, exert enhanced tumor killing. Used in such combination therapies, and at lower concentrations, current data with agonistic anti-CD137 antibodies look promising.\(^{20}\)

The potency of the CD137 co-stimulatory signal also became evident in the evolution of chimeric antigen receptors (CARs). The inclusion of the cytoplasmic CD137 signaling domain into the second generation CARs greatly enhanced their efficacy in augmenting CAR-mediated T cell responses by reducing exhaustion and enhancing the persistence of CAR T cells.\(^{21-23}\)

In addition, the immune-stimulatory activity of agonistic anti-CD137 antibodies is also manifested in their strong enhancement of anti-viral immune responses, as demonstrated for influenza, pox virus, respiratory syncytia virus and human immunodeficiency virus among others.\(^{24,25}\) Even under physiological conditions CD137–CD137L interaction is required to mount a proper anti-viral immune response.\(^{26}\) Furthermore, agonistic anti-CD137 antibodies have been shown to accelerate rejection of cardiac and intestinal allografts as well as of skin transplants.\(^{27,28}\) The potent enhancement of T cell and NK cell activity by CD137 signaling explains the antitumor effects of agonistic anti-CD137 antibodies in clinical applications.

Injection of an agonistic anti-CD137 antibody into otherwise untreated mice led to an increase in the CD8\(^{+}\) T cell number and a reduction in the B cell number. Furthermore, these mice developed liver pathology that was dependent on CD8\(^{+}\) T cells, IFN\(\gamma\) and TNF. This phenotype can be explained by the agonistic anti-CD137 antibody inducing a type 1, cell-mediated response.\(^{29}\)

Two studies identified a time dependence in the therapeutic activity of agonistic anti-CD137 antibodies. Administration of anti-CD137 antibody to mice infected with lymphocytic choriomeningitis virus or influenza within the first three days of infection led to a complete collapse of anti-viral immunity, resulting in high mortality. In contrast, antibody administration 3 days post infection gave rise to a robust immune response resulting in an effective elimination of the viral load in all mice. It was found that antibody administration within the first 3 days post infection had caused a deletion of CD4\(^{+}\) and CD8\(^{+}\) T cells.\(^{30}\) Similarly, anti-CD137 antibody administration to mice with lymphoma xenografts within 3 days of tumor cell injection did not cause tumor rejection, while antibody administration at later time points resulted in an effective elimination of the tumors, and increased survival of the mice.\(^{31}\) This time dependence may indicate that a certain degree of T cell activation is required for a successful co-stimulation by CD137, otherwise T cell death may ensue. Alternatively, stimulation of CD137 on certain DC during priming of an immune response may cause T cell death.\(^{32}\) Although, the reasons for this time dependence of CD137 co-stimulation are not yet known, these findings are consistent with the notion that the CD137 signal in T cells promotes a Th1/Tc1 response, since it is type 1, cell-mediated immunity that is required for the clearance of viral infections and the elimination of tumors (Fig. 1).

A time-dependent modulation of CD137–CD137L interaction has also been identified in murine graft vs. host disease (GVHD) models, where the administration of anti-CD137 or anti-CD137L antibody elicits different effects on acute versus chronic GVHD. Neutralization of CD137L by antagonistic anti-CD137L antibodies inhibited acute GVHD by reducing proliferation, IFN\(\gamma\) secretion and cytotoxicity of CD8\(^{+}\) T cells, which reduced mortality in the mice. However, inhibition of CD137L, in chronic GVHD exacerbated pathology. In chronic GVHD, similarly as in acute GVHD, the CD8\(^{+}\) T cell activity was inhibited, but the CD4\(^{+}\) T cell response was increased. This resulted in an increased number of IL-4-expressing CD4\(^{+}\) T cells, and promoted a Th2 cell differentiation and an early production of auto-antibodies.\(^{33}\) In contrast, and as one would expect, stimulation of CD137 by agonistic antibodies increased acute GVHD, resulting in increased mortality,\(^{34}\) whereas CD137 stimulation ameliorated chronic GVHD by eliminating CD4\(^{+}\) T cells via activation-induced cell death.\(^{35}\)

The data from the murine GVHD models demonstrate that CD137–CD137L interaction during acute GVHD exacerbate disease activity by promoting type 1 immunity. In contrast, chronic GVHD, which is mediated to a larger extent by a humoral response,\(^{36}\) is ameliorated by the CD137 agonist-induced cellular response. Therefore, the studies on GVHD provide additional evidence that CD137–CD137L interaction drives a type 1, cell-mediated immune response.

**Reverse CD137 ligand signaling in APC strengthens type 1, cell-mediated immune responses**

The CD137 receptor/ligand system has the ability to signal bidirectionally, a characteristic shared with several other members of the tumor necrosis factor receptor/ligand families (Fig. 1). The molecular basis of bidirectional signaling is that CD137L, just as CD137, is expressed as a transmembrane protein on the cell surface, which allows it to transmit signals into the cells it is expressed on, a process referred to as reverse signaling.\(^{37}\) Such bidirectional interaction allows for a two-way exchange of signals between the receptor- and ligand-bearing cells, and thus a simultaneous fine-tuning and modulation of their activities.

CD137L is expressed by all types of APC, and it delivers a stimulatory signal into APC, referred to as reverse CD137L signaling (Fig. 1). In monocytes, the reverse CD137L signal induces activation and the secretion of pro-inflammatory cytokines such as TNF, IL-6 and IL-8, while it inhibits the anti-inflammatory cytokine IL-10.\(^{38}\) Furthermore, reverse CD137L signaling results in increased survival and proliferation of monocytes\(^{39,40}\) and stimulates their migration and extravasation.\(^{41,42}\) These activities lead to an increased influx of inflammatory monocytes into tissues.

When monocytes encounter CD137-expressing cells in the tissue, reverse CD137L signaling into monocytes may induce their differentiation to inflammatory dendritic cells (DC).\(^{43,44}\) These CD137L-stimulated DC (in short, CD137L-DC) are strong inducers of Th1/Tc1 immune responses which potently stimulate the proliferation of T cells that produce high levels of IFN\(\gamma\). CD137L-DC are 2–3 times more potent than GM-CSF + IL-4 derived DC in activating allogeneic T cells\(^{44}\) and in enhancing the cytolytic activity of autologous T cells in an antigen-specific manner.\(^{45}\) Reverse CD137L signaling also induces the maturation of monocyte-derived DC generated by GM-CSF + IL-4.\(^{46}\) Therefore, monocytes that have migrated to an
inflamed tissue under the influence of reverse CD137L signaling, are prone to differentiate to inflammatory DC, also under the influence of reverse CD137L signaling. The influence of reverse CD137L signaling on myelopoiesis is not restricted to mature cells. In haematopoietic progenitor cells, reverse CD137L signaling induces myelopoiesis, which occurs especially during infections. This allows for the generation of more inflammatory APC which can assist in the elimination of the pathogens. CD137L signaling in DC induces the secretion of IL-12p70 but has no effect on the secretion of IL-5 and IL-10, thus indicating that it promotes polarization toward Tc1. These data on reverse CD137L signaling are based on in vitro experiments, and await confirmation in vivo.

However, current data suggest that forward signaling through CD137 as well as reverse signaling through CD137L promote and strengthen cell-mediated, type 1 immune responses. Disabling CD137–CD137L driven type 1 immune responses facilitates the escape of tumors from immune surveillance

An inflammatory environment is known to favor cancer progression. Specifically, it is the chronic inflammation associated with a type 2 immune response that promotes cancer cell survival while type 1 immune responses, which are associated with acute inflammation, are detrimental to cancer. A type 1, cell-mediated immune response is the main immune threat for malignant cells. Therefore, blunting a type 1 immune response is essential for a cancer to escape immune surveillance. Since CD137–CD137L interaction is one of the main drivers of type 1 immune responses, it is not surprising that cancers have developed diverse mechanisms to inhibit CD137 and CD137L signaling. In chronic lymphocytic leukemia (CLL) high levels of soluble CD137 are secreted which is antagonistic, as it binds to CD137L, thereby blocking the interaction of CD137L on APC with CD137 on the surface of activated T and NK cells. Thus, high levels of soluble CD137 decrease CD137-mediated costimulation of an anti-CLL immune response.

A different mechanism to disable CD137 co-stimulation is found in Hodgkin lymphoma. Hodgkin and Reed Sternberg cells, the malignant cells in Hodgkin lymphoma, express CD137 ectopically, which allows them to transfer CD137 to CD137L-expressing APC by trogocytosis. The CD137–CD137L complex is then internalized and undergoes degradation in the APC, resulting in the downregulation of CD137L, a major type 1 immunity-inducing factor, on the cell surface of APC, and thereby reduces an anti-Hodgkin lymphoma immune response. The trogocytic transfer of CD137 and the subsequent removal of T cell co-stimulation is a likely mechanism that regulates the activity of the CD137–CD137L system under physiological conditions, but is usurped by Hodgkin and Reed Sternberg cells in Hodgkin lymphoma to escape immune surveillance.

Further evidence for a role of CD137 and CD137L in antitumor immunity comes from a study which found that CD137L-deficient mice are prone to develop B cell lymphomas, and concluded that CD137L acts as a tumor suppressor. It identified as underlying mechanism the enhanced expression of growth-promoting genes in germinal center B cells that are normally inhibited by CD137L. Whether a reduced type 1, cell-mediated immune response, caused by the lack of CD137L, contributed to the emergence of lymphomas was not investigated in that study.

Reverse CD137L signaling also impacts the development of acute myeloid leukemia (AML). When CD137L on AML cells is cross linked by CD137 on NK cells, reverse CD137L signaling into AML cells induces IL-10 and TNF, which inhibit NK cell activity, and facilitate escape of AML cells from immune surveillance.

Figure 1. Schematic representation of bidirectional signal transduction for the CD137 receptor/ligand system and its effects on antigen presenting cells (APC), T cells and natural killer (NK) cells.
surveillance.\textsuperscript{56} Another study demonstrated reverse CD137L signaling into AML cells induces differentiation, resulting in reduced proliferation, and suggested this approach to be explored as a novel differentiation therapy for AML.\textsuperscript{57} In summary, the data from the role of CD137 and CD137L in cancer further support the notion of CD137–CD137L interaction promoting type 1, cell-mediated immune responses.

**CD137 agonists ameliorate autoimmune disease in murine models**

CD137–CD137L interaction as a main driver of type 1, cell-mediated immune responses explains the puzzling observation that the very same agonistic anti-CD137 antibodies which enhance antitumor and anti-pathogen immune responses and transplant rejections, are also able to ameliorate autoimmune diseases in many murine models, including experimental auto-immune encephalomyelitis,\textsuperscript{58} systemic lupus erythematosus,\textsuperscript{59,60} collagen-induced arthritis,\textsuperscript{61,62} uveoretinitis,\textsuperscript{63} allergic airway inflammation and asthma,\textsuperscript{64,65} inflammatory bowel disease\textsuperscript{66} and chronic graft vs. host disease.\textsuperscript{35}

Several mechanisms for the immune inhibitory effects of agonistic anti-CD137 antibodies in autoimmune disease models have been demonstrated. These include the induction of CD11c\textsuperscript{+} CD8\textsuperscript{+} T cells that stimulate indoleamine-pyrorrole 2,3-dioxygenase (IDO) in APC,\textsuperscript{62} the enhancement of Th cell activity\textsuperscript{67} and of regulatory DC activity,\textsuperscript{68} CD4\textsuperscript{+} T cell inhibition\textsuperscript{64,65} or elimination\textsuperscript{35} and immune deviation to the novel subset of Eomesoderm\textsuperscript{+} helper T cells.\textsuperscript{70} However, the key question still remains unresolved: Under what conditions does an agonistic anti-CD137 antibody induce these immune inhibitory mechanisms instead of activating immune responses that lead to tumor regression, pathogen clearance or transplant rejection? Why are agonistic anti-CD137 antibodies not inducing immune inhibitory mechanisms in a tumor setting, and why are they not enhancing immune activity in autoimmune disease?

**The CD137–CD137L working model CD137- and CD137L-mediated T cell polarization**

There is consensus in the published literature that CD137 signals promote CD8\textsuperscript{+} T cell proliferation and activation. In contrast, different and conflicting results of CD137 signaling in CD4\textsuperscript{+} T cells have been reported, ranging from activation to inhibition and induction of cell death.\textsuperscript{71} Despite that, little to no distinction has been made between different CD4\textsuperscript{+} T cell subsets, even though the immune activities of CD4\textsuperscript{+} T cells can vary profoundly depending on how they are polarized. We propose that it is the Th1-polarized CD4\textsuperscript{+} T cells that are co-stimulated by CD137 signals which—together with activated Tc1 CD8\textsuperscript{+} T cells and activated NK cells—inhibit other T cell subsets (Fig. 2). This notion is consistent with the observation that agonistic anti-CD137 antibodies suppressed the induction of Th2-dependent antibodies to sheep red blood cells in mice\textsuperscript{72} and to ovalbumin in non-human primates.\textsuperscript{73}

In type 2-dominated autoimmune diseases, such as systemic lupus erythematosus, CD137 signaling into T cells drives a type 1 polarization, with subsequent IFN\textgamma secretion, which in turn inhibits immunoglobulin synthesis and reduces the disease index. This has been demonstrated in two different murine lupus models, the CD95-deficient lymphoproliferative (lpr) mice\textsuperscript{50} and the New Zealand Black x New Zealand White F\textsubscript{1} mice.\textsuperscript{74} In collagen-induced arthritis, antibodies against collagen II play an important role in pathogenesis, and agonistic anti-CD137 antibodies inhibited auto-antibody production and reduced clinical scores.\textsuperscript{61,62} A similar therapeutic effect of agonistic anti-CD137 antibodies has been reported for type 2-driven allergic inflammation of the lung, where CD137 stimulation resulted in a decrease in the levels of the Th2 cytokines IL-4 and IL-5, and of IgE, as well as a reduced T cell and eosinophil infiltration into the lung and airways.\textsuperscript{64,65} Sun \textit{et al.}, 2006 claim that an agonistic anti-CD137 antibody directly inhibits Th2 CD4\textsuperscript{+} T cells.\textsuperscript{64} However, this claim is challenging to prove since Th2 CD4\textsuperscript{+} T cells cannot readily be separated from Th1 CD4\textsuperscript{+} T cells.

Inhibition of type 2 immune responses by agonistic anti-CD137 antibodies may occur by several mechanisms, such as through stimulation of existing Th1-polarized CD4\textsuperscript{+} T cells and subsequent inhibition (via induction of anergy or apoptosis) of Th2-polarized CD4\textsuperscript{+} T cells by IFN\textgamma and other Th1-promoting factors. Another possible mechanism could be the prevention of Th2 cell polarization by anti-CD137 antibody during priming of naive CD4\textsuperscript{+} T cells.

For autoimmune diseases which are mainly driven by a type 1 response, such as type 1 diabetes, it is predicted that the Th1/Tc1-promoting activity of an agonistic anti-CD137 antibody would exacerbate disease. Indeed, CD137 stimulation by an agonistic anti-CD137 single chain fragment worsened disease in non-obese diabetic (NOD) mice,\textsuperscript{75} whereas soluble CD137 prevented diabetes.\textsuperscript{76}

This type 1 polarization by CD137–CD137L interaction also explains the seemingly contradictory observations in gene-modified mice, such as the exacerbation of lupus in the absence of CD137,\textsuperscript{77} and the inhibition of experimental auto-immune encephalomyelitis in the absence of CD137L.\textsuperscript{78} In the lupus-inflicted lpr, CD137\textsuperscript{−/-} mice, the lack of the CD137 signal prevented a type 1-driven counterbalance of the pathogenic type 2 immune response. Conversely, in the CD137L\textsuperscript{−/-} mice, the lack of the CD137 signal restricted the development of a pathogenic type 1 immune response which could have caused experimental autoimmune encephalomyelitis.

**Predictions and future directions**

A prediction of this model, i.e. CD137–CD137L interaction being a pivotal driver for type 1, cell-mediated immune responses, is that neutralization of CD137L would also ameliorate autoimmune diseases (Fig. 3). This prediction is supported by studies in which an antagonistic anti-CD137L antibody has been shown to reduce collagen-induced arthritis\textsuperscript{62} and LPS-induced sepsis\textsuperscript{79} in mice. Furthermore, blockade of CD137L by a recombinant CD137-Fc fusion protein inhibited allograft rejection by CD8\textsuperscript{+} T cells.\textsuperscript{28} Both, agonistic anti-CD137 antibodies as well as antagonistic anti-CD137L antibodies can reduce inflammatory signals through CD137L since both are able to block binding of CD137 to CD137L. But since agonistic anti-CD137 antibodies induce in addition a type 1
polarization, they should be more potent. This is exactly what has been observed experimentally in collagen-induced arthritis in which an agonistic anti-CD137 antibody proved to be significantly more effective than an antagonistic anti-CD137L antibody in reducing pro-inflammatory cytokine release, proliferation of collagen-specific T cells and clinical scores.62

An antagonistic anti-CD137 antibody is expected to block CD137–CD137L interaction, and to exert similar effects as an antagonistic anti-CD137L antibody, i.e. be less effective in ameliorating autoimmune diseases that have a strong type 2/B cell involvement than an agonistic anti-CD137 antibody (Fig. 3). However, for type 1-dominated auto-immune diseases, an antagonistic anti-CD137 or anti-CD137L antibody would be the preferred treatment. The same would be applicable for pathogen-induced type 1 immune pathologies, and for the prevention of transplant rejection. In these situations, an agonistic anti-CD137 antibody cannot be used as it would exacerbate the type 1 immunity-driven disease.

Figure 2. The effects of agonistic anti-CD137 antibodies on type 1 polarization which promotes (green arrows) anticancer immune responses and inhibits (red lines) type 2-mediated autoimmune reactions.

Figure 3. The effects of inhibition of CD137–CD137L interaction by antagonistic anti-CD137 or anti-CD137L antibodies on the bidirectional signal transduction for the CD137 receptor/ligand system is depicted exemplary for the case of an APC–T cell interaction.
There are some observations that do not fit the model proposed here. For example, CD137 stimulation by an agonistic anti-CD137 antibody inhibited trinitrobenzene sulphonic acid (TNBS)—induced colitis in mice.66 Since TNBS-induced colitis is considered to be a type 1-mediated autoimmune disease, a worsening rather than an inhibition of the disease would have been expected by CD137 co-stimulation. Currently, the reason for this discrepancy is not known.

Due to the bidirectional signaling in the CD137 receptor/ligand system, engaging CD137 may not only enhance T cell and NK cell activity, but it also influences the activities of the CD137L-expressing cells. While enhancing T cell and NK cell activities, an agonistic anti-CD137 antibody can block access of CD137L into CD137L-expressing cells. While enhancing T cell and NK cell activity, but it also in

References

1. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, Mittler RS, Chen L. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997; 3:682-5; PMID:9167498; http://dx.doi.org/10.1038/nm0697-682

2. Vinay DS, Kwon BS. 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy. BMB Reports 2014; 47:122-9; PMID:24496671; http://dx.doi.org/10.5483/BMBRep.2014.47.3.283

3. Wang S, Chen L. Immunobiology of cancer therapies targeting CD137 and B7-H1/PD-1 cosignal pathways. Current topics in microbiology and immunology 2011; 344:245-67; PMID:20582331; http://dx.doi.org/10.1007/82_2010_81

4. Srivastava AK, Dinc G, Sharma RK, Yolcu ES, Zhao H, Shirwan H, SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines. Cancer Res 2014; 74:6441-51; PMID:25252915; http://dx.doi.org/10.1158/0008-5472.CAN-14-1768-A

5. Schrand B, Berezhnoy A, Brenneman R, Williams A, Levay A, Kong LY, Rao G, Zhou S, Heimberger AB, Gilboa E. Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy. Cancer Immunol Res 2014; 2:867-77; PMID:24938283; http://dx.doi.org/10.1158/2326-6066.CIR-14-0007

6. Guinn BA, DeBenedette MA, Watts TH, Berinstein NL. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J Immunol 1999; 162:5003-10; PMID:10202049

7. Zhang H, Merchant MS, Chua KS, Khanna C, Helman LJ, Telford B, Ward Y, Summers J, Toretsky J, Thomas EK et al. Tumor expression of 4-1BB ligand sustains tumor lytic T cells. Cancer Biology Ther 2003; 2:579-86; PMID:14614331; http://dx.doi.org/10.1016/j.cbt.2003.05.013

8. McGray AJ, Bernard D, Hallett R, Kelly R, Jha M, Gregory C, Bassett JD, Hassell JA, Pare G, Wan Y et al. Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patients. Oncoimmunology 2012; 1:419-31; PMID:22754760; http://dx.doi.org/10.4161/onci.19534

9. Houot R, Kohrt H. CD137 stimulation enhances the vaccine effect of anti-tumor antibodies. Oncoimmunology 2014; 3:e941740; PMID:25610724; http://dx.doi.org/10.4161/21624011.2014.941740

10. Kwon BS, Weissman SM. cDNA sequences of two inducible T-cell genes. ProcNatAcadSciUSA 1989; 86:1963-7; PMID:2784565; http://dx.doi.org/10.1073/pnas.86.6.1963

11. Schwarz H, Tuckwell J, Lotz M. A receptor induced by lymphocyte activation (ILA): a new member of the human nerve-growth-factor/tumor-necrosis-factor receptor family. Gene 1993; 134:295-8; PMID:8262389; http://dx.doi.org/10.1016/0378-1119(93)90110-O

12. Takahashi C, Mittler RS, Vella AT. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunol 1999; 162:5037-40; PMID:10227968

13. Ye Q, Song DG, Poussin M, Yamamoto T, Best A, Li C, Coukos G, Powell DJ Jr. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin Cancer Res 2014; 20:44-55; PMID:24045181; http://dx.doi.org/10.1158/1078-0432.CCR-13-0945

14. Aranda F, Vacchelli E, Eggermont A, Galon J, Fridman WH, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014; 3:e27297; PMID:24701370; http://dx.doi.org/10.4161/onci.27297

15. Ascierto PA, Simeone E, Sznol M, Fu XY, Melero I. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Sem Oncol 2010; 37:508-16; PMID:21074066; http://dx.doi.org/10.1053/j.semoncol.2010.09.008

16. Melero I, Johnston JV, Shuford WW, Mittler RS, Chen L. NK.1.1 cells express 4-1BB (CD137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol 1998; 190:167-72; PMID:9878117; http://dx.doi.org/10.1006/cimm.1998.1396

17. Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, Müller A, Pachynski R, Czerswinski D, Coutre S et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 2011; 117:2423-32; PMID:21193697; http://dx.doi.org/10.1182/blood-2010-08-301945

18. Kohrt HE, Colevas AD, Houot R, Weiskopf K, Goldstein MJ, Lund P, Mueller A, Sagiv-Barfi I, Marabelle A, Lira R et al. Targeting CD137 enhances the efficacy of cetuximab. J Clin Inv 2014; 124:2686-82; PMID:24837434; http://dx.doi.org/10.1172/JCI73014

19. Kobayashi T, Doff BL, Rearden RC, Leggett GR, Mamontello SR. NK cell-targeted vaccination plus anti-4-1BB antibody generates persistent CD8 T cell immunity against B cell lymphoma. Oncoimmunology 2015; 4:e990793; PMID:25949907; http://dx.doi.org/10.4161/2162042X.2014.990793

20. Yonezawa A, Dutt S, Chester C, Kim J, Kohrt HE. Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy. Clin Cancer Res 2015; 21:613367-6; PMID:25252915; http://dx.doi.org/10.1158/0008-5472.CAN-14-1768-A

Disclosure of potential conflicts of interest

No potential conflicts of interest were disclosed.

Funding

This work was supported by grant NMRC/CBRG/0066/2014 from the National Medical Research Council, Singapore.
21. Imai C, Mihrara K, Andreansky M, Nicholson IC, Pui CH, Geiger TL, Campana D. Chimeric receptors with 4-1BB signaling capacity promote potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004; 18:667-84; PMID:14961035; http://dx.doi.org/10.1038/sj.lie.2102402

22. Campana D, Schwarz H, Imai C. 4-1BB chimeric antigen receptors. Cancer J 2014; 20:134-40; PMID:24667959; http://dx.doi.org/10.1097/PPO.0000000000000228

23. Long AH, Hao WM, Shern JF, Warhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwarra VR et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 2015; 21:581-90; PMID:25939063; http://dx.doi.org/10.1038/nm.3838

24. Mbanwi AN, Watts TH. Costimulatory TNFR family members in control of viral infection: outstanding questions. Sem Immunol 2014; 26:210-9; PMID:24910294; http://dx.doi.org/10.1016/j.smim.2014.05.001

25. Halstead ES, Mueller YM, Altman JD, Katsikis PD. In vivo stimulation of CD137 broadens primary antiviral CD8+ T cell responses. Nat Immunol 2002; 3:536-41; PMID:12021777; http://dx.doi.org/10.1038/ni798

26. Lin GH, Sedgmen BJ, Moraes TJ, Snell LM, Topham DJ, Watts TH. Endogenous 4-1BB ligand plays a critical role in protection from influenza-induced disease. J Immunol 2009; 182:934-47; PMID:19124736; http://dx.doi.org/10.4049/jimmunol.182.2.934

27. Shuford WW, Klussman K, Tichrcher DD, Loo DT, Chalupny J, Siadak JT, Irish JM, Torchia JA, Kolstad A, Chen L et al. Therapeutic effect of CD137 costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 2015; 21:581-90; PMID:25939063; http://dx.doi.org/10.1038/nm.3838

28. Wang J, Guo Z, Dong Y, Hart J, Adams A, Larsen CP, Mittler RS, Newell KA. Role of 4-1BB in allograft rejection mediated by CD8+ T cells. Am J Transplant 2003; 3:543-51; PMID:12752310; http://dx.doi.org/10.1038/sj.a別160.6143.2003.00088.x

29. Niu L, Strahotin S, Hewes B, Zhang B, Zhang Y, Archer D, Spencer T, Dillehay D, Kwon B, Chen L et al. Cytokine-mediated disruption of anemia, and thrombocytopenia in anti-CD137-treated mice. J Immunol 2004; 18:676-84; PMID:14961035; http://dx.doi.org/10.1038/sj.lie.2102402

30. Zhanh B, Maris CH, Foell J, Whitmore J, Niu L, Song J, Kwon BS, Vella AT, Ahmed R, Jacob J et al. Immune suppression or enhancement by anti-CD137 ligand monoclonal antibody results in differential effect on development of murine acute and chronic graft-versus-host disease by inducing activation-induced cell death of donor CD4+ T cells. Blood 2005; 105:2206-13; PMID:15522958; http://dx.doi.org/10.1182/blood-2004-06-2080

31. Houot R, Goldstein MJ, Kohrt HE, Myklebust JH, Alizadeh AA, Lin OW, Shaughnessy J. Dendritic cells, in

32. Zhang B, Zhang Y, Niu L, Strahotin S, Hewes B, Zhang B, Zhang Y, Archer D, Spencer T, Dillehay D, Kwon B, Chen L et al. Cytokine-mediated disruption of anemia, and thrombocytopenia in anti-CD137-treated mice. J Immunol 2004; 18:676-84; PMID:14961035; http://dx.doi.org/10.1038/sj.lie.2102402

33. Nozawa K, Ohata J, Sakurai J, Hashimoto H, Miyajima H, Yagita H, Okumura K, Azuma M. Preferential blockade of CD8(+) T cell responses by administration of anti-CD137 ligand monoclonal antibody results in differential effect on development of murine acute and chronic graft-versus-host disease. J Immunol 2001; 167:4981-6; PMID:11673305; http://dx.doi.org/10.4049/jimmunol.167.9.4981

34. Kim W, Kim J, Jung D, Kim H, Choi HJ, Choi HR, Kwon B. Induction of lethal graft-versus-host disease by anti-CD137 monoclonal antibody in mice prone to chronic graft-versus-host disease. Blood 2009; 115:306-14; PMID:19203721; http://dx.doi.org/10.1182/blood-2008-11.035

35. Kim J, Choi WS, La S, Suh JH, Kim BS, Cho HR, Kwon BS, Kwon B. Stimulation with 4-1BB (CD137) inhibits chronic graft-versus-host disease by inducing activation-induced cell death of donor CD4+ T cells. Blood 2005; 105:2206-13; PMID:15522958; http://dx.doi.org/10.1182/blood-2004-06-2080
eliminating CD137 ligand expression. Cancer Res 2013; 73:652-61; PMID:23204227; http://dx.doi.org/10.1158/0008-5472.CAN-12-3849

54. Shao Z, Harfuddin Z, Pang WL, Nickles E, Koh LK, Schwarz H. Trogocytic CD137 transfer causes an internalization of CD137 ligand on murine APCs leading to reduced T cell costimulation. J Leukoc Biol 2015; PMID:25765680

55. Middendorp S, Xiao Y, Song JY, Peperzak V, Krijger PH, Jacobs H, Borst J. Mice deficient for CD137 ligand are predisposed to develop germinal center-derived B-cell lymphoma. Blood 2009; 115:2280-9; PMID:19608748; http://dx.doi.org/10.1182/blood-2009-03-208215

56. Baessler T, Charton JE, Schmiedel BJ, Grunebach F, Krusch M, Polte T, Foell J, Werner C, Hoymann HG, Braun A, Burdach S, Mittler RS, Hoffmann MK, Dannecker GE. Engagement of the CD137 costimulatory molecule inhibits and reverses the autoimmune disease. Nat Med 2002; 8:1405-13; PMID:12426559; http://dx.doi.org/10.1038/nm1202-796

57. Myers L, Takahashi C, Mittler RS, Rossi RJ, Vella AT. Effector CD8 T cells possess suppressor function after 4-1BB and Toll-like receptor triggering. Proc Nat Acad Sci USA 2003; 100:5348-53; PMID:12695569; http://dx.doi.org/10.1073/pnas.0337611100

58. Sun Y, Blink SE, Liu W, Lee Y, Chen B, Solway J, Weinstock J, Chen L, Fu YX. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. J Immunol 2002; 168:1457-65; PMID:11801689; http://dx.doi.org/10.4049/jimmunol.168.3.1457

59. Sun Y, Lin X, Chen HM, Wu Q, Subudhi SK, Chen L, Fu YX. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. J Immunol 2002; 168:1457-65; PMID:11801689; http://dx.doi.org/10.4049/jimmunol.168.3.1457

60. Foell JL, ez-Mendiondo BI, Diez OH, Holzer U, Ruck P, Bapat AS, Consonni E, Hinerman JM, Herr AB, Ridgway WM. Recombinant soluble CD137 ligand mediating anti-CD40L IgM+regulatory B cells suppress antigen-induced humoral immune responses in vivo through the induction of helper T cell anergy. J Exp Med 1999; 190:1535-40; PMID:10562327; http://dx.doi.org/10.1084/jem.190.10.1535

61. Foell J, Strahotin S, O’Neill SP, McCausland MM, Subudhi C, Haber M, Chander PN, Bapat AS, Vinay DS, Chaudhuri AK, Payne JS, Yoon SK et al. A humanized anti-4-1BB monoclonal antibody suppresses antigen-induced humoral immune response in nonhuman primates. J Immunother 2000; 23:613-21; PMID:11186149; http://dx.doi.org/10.1002/1097-0023(20001000)00:065X.2000100000002

62. Baessler T, Charton JE, Schmiedel BJ, Grunebach F, Krusch M, Polte T, Foell J, Werner C, Hoymann HG, Braun A, Burdach S, Mittler RS, Hoffmann MK, Dannecker GE. Engagement of the CD137 costimulatory molecule inhibits and reverses the autoimmune process in collagen-induced arthritis and abrogates lasting disease resistance. Immunol 2004; 113:89-98; PMID:15312139; http://dx.doi.org/10.1011/immunol.2004.01952

63. Choi BK, Asai T, Vinay DS, Kim YH, Kwon BS. Role of endogenous 4-1BB in the development of systemic lupus erythematosus. Immuology 2007; 122:394-400; PMID:17608689; http://dx.doi.org/10.1084/jem.2006065X.2009.00765.x

64. Foell J, McCausland M, Burch J, Corriazia N, Yan XJ, Suwcn C, O’Neil SP, Hoffmann MK, Mittler RS. CD137-mediated T cell co-stimulation terminates existing autoimmune disease in SLE-prone NZB/NZW F1 mice. Ann NY Acad Sci 2003; 987:230-5; PMID:12727643; http://dx.doi.org/10.1111/j.1749-6632.2003.tb06052.x

65. Polte T, Foell J, Werner C, Hoymann HG, Braun A, Burdach S, Mittler RS, Hansen G. CD137-mediated immunotherapy for allergic asthma. J Immunol 2006; 177:814-21; PMID:16899371; http://dx.doi.org/10.1523/JNEUROSCI.2473-12.2012

66. Palma C, Vendetti S, Cassone A. Role of 4-1BB receptor in the control of experimental autoimmune encephalomyelitis. J Neurosci 2006; 26:192-215; PMID:16942622; http://dx.doi.org/10.1172/JCI23792

67. Martinez Gomez JM, Croxford JL, Yeo KP, Angeli V, Schwarz H, Gasser S. Development of experimental autoimmune encephalomyelitis critically depends on CD137 ligand signaling. J Neurosci 2012; 32:18246-52; PMID:23238738; http://dx.doi.org/10.1523/JNEUROSCI.2473-12.2012

68. Bang BR, Kim SJ, Yagita H, Croft M, Kang YJ. Inhibition of 4-1BBL-induced sepsis in mice. Eur J Immunol 2015; 45:886-92; PMID:25501291; http://dx.doi.org/10.1002/eji.201445174

69. Myers L, Takahashi C, Mittler RS, Rossi RJ, Vella AT. Effector CD8 T cells possess suppressor function after 4-1BB and Toll-like receptor triggering. Proc Nat Acad Sci USA 2003; 100:5348-53; PMID:12695569; http://dx.doi.org/10.1073/pnas.0337611100

70. Curran MA, Geiger TL, Montalvo W, Kim M, Reiner SL, Al-Shamkani A, Sun JC, Allison JP. Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesoderm. J Exp Med 2013; 210:743-55; PMID:23547098; http://dx.doi.org/10.1084/jem.20121190

71. Wang C, Lin GH, McPherson AJ, Watts TH. Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunol Rev 2009; 229:192-215; PMID:19426223; http://dx.doi.org/10.1111/j.1600-065X.2009.00765.x

72. Mittler RS, Bailey TS, Klussman K, Trailsmith MD, Hoffmann MK. Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy. J Exp Med 1999; 190:1535-40; PMID:10562327; http://dx.doi.org/10.1084/jem.190.10.1535

73. Neill FL, Lin WD, Roifler SR, Hung JT, Sung HS, Wang CH, Cheng TL, Tsou SC, Hsi SC, Chen KL. Anti-4-1BB-based immunotherapy for autoimmune diabetes: lessons from a transgenic non-obese diabetic (NOD) model. J Autoimmun 2003; 21:247-54; PMID:12750400; http://dx.doi.org/10.1016/S0896-8411(03)00111-7

74. Sytwu HK, Lin WD, Roifler SR, Hung JT, Sung HS, Wang CH, Cheng TL, Tsou SC, Hsi SC, Chen KL. Anti-4-1BB-based immunotherapy for autoimmune diabetes: lessons from a transgenic non-obese diabetic (NOD) model. J Autoimmun 2003; 21:247-54; PMID:14599849; http://dx.doi.org/10.1006/jim.20121190

75. Consonni E, Hinerman JM, Herr AB, Ridgway WM. Recombinant soluble CD137 ligand prevents type I diabetes in nonobese diabetic mice. J Autoimmun 2003; 21:247-54; PMID:14599849; http://dx.doi.org/10.1006/jim.20121190